ALTHX.PA
Price:
$1.84
Market Cap:
$17.33M
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Industry
Medical - Pharmaceuticals
IPO Date
2017-10-30
Stock Exchange
PAR
Ticker
ALTHX.PA
According to THX Pharma’s latest financial reports and current stock price. The company's current PE Ratio is -5.41. This represents a change of -281.91% compared to the average of 2.97 of the last 4 quarters.
The mean historical PE Ratio of THX Pharma over the last ten years is -9.45. The current -5.41 PE Ratio has changed 5.62% with respect to the historical average. Over the past ten years (40 quarters), ALTHX.PA's PE Ratio was at its highest in in the June 2024 quarter at 16.16. The PE Ratio was at its lowest in in the January 2015 quarter at -50.74.
Average
-9.45
Median
-5.86
Minimum
-26.74
Maximum
-1.27
Discovering the peaks and valleys of THX Pharma PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 707.43%
Maximum Annual PE Ratio = -1.27
Minimum Annual Increase = -81.45%
Minimum Annual PE Ratio = -26.74
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -2.80 | 119.64% |
| 2023 | -1.27 | -10.15% |
| 2022 | -1.42 | -52.63% |
| 2021 | -2.99 | -81.07% |
| 2020 | -15.80 | 707.43% |
| 2019 | -1.96 | -81.45% |
| 2018 | -10.54 | -52.65% |
| 2017 | -22.27 | 154.85% |
| 2016 | -8.74 | -67.31% |
The current PE Ratio of THX Pharma (ALTHX.PA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.83
5-year avg
-4.85
10-year avg
-9.45
THX Pharma’s PE Ratio is less than Poxel S.A. (-0.26), greater than Ikonisys S.A. (-7.81), less than Aelis Farma S.A. (-1.79), less than NFL Biosciences S.A. (-5.29), less than Valbiotis S.A. (-1.11), less than Intrasense S.A. (-2.08), less than GenSight Biologics S.A. (-0.80), less than Predilife S.A. (-2.93), less than Biosynex S.A. (-0.14), less than Bluelinea S.A. (-4.45),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.26 | $12.46M | |
| -7.81 | $23.68M | |
| -1.79 | $14.64M | |
| -5.29 | $14.19M | |
| -1.11 | $16.75M | |
| -2.08 | $13.48M | |
| -0.80 | $19.65M | |
| -2.93 | $12.77M | |
| -0.14 | $8.77M | |
| -4.45 | $8.43M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like THX Pharma using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like THX Pharma or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is THX Pharma's PE Ratio?
How is the PE Ratio calculated for THX Pharma (ALTHX.PA)?
What is the highest PE Ratio for THX Pharma (ALTHX.PA)?
What is the 3-year average PE Ratio for THX Pharma (ALTHX.PA)?
What is the 5-year average PE Ratio for THX Pharma (ALTHX.PA)?
How does the current PE Ratio for THX Pharma (ALTHX.PA) compare to its historical average?